Foresite Capital Management IV, LLC
Foresite Capital Management IV, LLC reported 6 US-listed holdings worth $290.2 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Pharvaris N V (57.0%), Cytokinetics Inc. (21.0%) and Eikon Therapeutics Inc. (8.7%). Against the quarter before, it opened 1 position, added to 2, trimmed 0 and sold out of 3.
The 6 largest of its 6 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +58.7% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 1
- Crinetics Pharmaceuticals in CRNX$5.6 million
Added to 2
- Cytokinetics Inc. CYTK+211,400 shares · +42%
- Relay Therapeutics Inc. RLAY+250,000 shares · +25%
Sold out of 3
- Lyell Immunopharma Inc. LYEL$16.1 million last quarter
- Alector Inc. ALEC$8.4 million last quarter
- Maze Therapeatics MAZE$4.7 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Pharvaris N V PHVS | 4.8M | $165.2 million | 56.95% | no change |
| Cytokinetics Inc. CYTK | 714.7K | $60.9 million | 20.98% | +211.4K |
| Eikon Therapeutics Inc. EIKN | 1.9M | $25.4 million | 8.74% | no change |
| Relay Therapeutics Inc. RLAY | 1.2M | $23.4 million | 8.06% | +250.0K |
| Xenon Pharmaceuticals Inc. XENE | 160.0K | $9.7 million | 3.33% | no change |
| Crinetics Pharmaceuticals in CRNX | 150.0K | $5.6 million | 1.93% | new |